Article Summary: Title: Nicotinamide Mononucleotide (NMN) Shows Potential in Treating Inflammatory Bowel Disease (IBD)
- Inflammatory bowel disease (IBD) is a chronic condition characterized by intestinal inflammation and various predisposing factors.
- Two main subtypes of IBD are Crohn's disease (CD) and ulcerative colitis (UC), which cause recurring symptoms such as abdominal pain and diarrhea.
- IBD can damage the intestinal epithelial barrier, gut morphology, and microbiota.
NMN and NAD+ in Disease Prevention and Treatment
- Nicotinamide adenine dinucleotide (NAD+) is a critical coenzyme involved in various physiological processes.
- Nicotinamide mononucleotide (NMN) is a precursor of NAD+ and has shown potential in preventing and treating age-related diseases.
- Previous studies have demonstrated the benefits of NMN in conditions like Alzheimer's disease, ischemia/reperfusion injury, and type 2 diabetes.
NMN and IBD
- The relationship between NAD+ metabolism in the intestine and IBD has not been extensively studied.
- NMN has the potential to regulate gut microbiota and protect intestinal mucosa.
- Researchers aim to evaluate the role of NMN in treating IBD using a colitis model.
Experimental Design and Results
- C57BL/6J mice were used to establish a colitis model induced by dextran sodium sulfate (DSS).
- Mice were divided into different groups and received NMN treatment via gavage.
- NMN administration improved the structure of inflamed intestines, restored colon length, enhanced barrier function, and reduced proinflammatory factors in serum.
- NMN also caused significant changes in the composition and abundance of gut microbiota, promoting beneficial bacteria and reducing harmful ones.
Implications and Conclusion
- The findings suggest that NMN may alleviate inflammation, improve intestinal permeability, and restore gut microbiota imbalance associated with IBD.
- NMN shows potential as a treatment option for IBD.
- Further research and clinical applications are warranted to explore the full benefits of NMN in IBD treatment.
Declaration of competing interest:
The authors declare no competing financial interests or personal relationships that could have influenced their work.
The study was supported by various funding sources in China, including the Natural Science Foundation of China and several provincial programs.
Dr. Quancai Sun is the handling editor responsible for managing the editorial process and ensuring the quality of the content in this section.
Title of paper: Treatment of inflammatory bowel disease: Potential effect of NMN on intestinal barrier and gut microbiota
Author(s): Huang P, Wang X, Wang S, Wu Z, Zhou Z, Shao G, Ren C, Kuang M, Zhou Y, Jiang A, Tang W, Miao J, Qian X, Gong A, Xu M.
Year published: 2022
Published in: Curr Res Food Sci
Original article can be found here.